These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38287902)

  • 1. Chelation of Mitochondrial Iron as an Antiparasitic Strategy.
    Arbon D; Mach J; Čadková A; Sipkova A; Stursa J; Klanicová K; Machado M; Ganter M; Levytska V; Sojka D; Truksa J; Werner L; Sutak R
    ACS Infect Dis; 2024 Feb; 10(2):676-687. PubMed ID: 38287902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
    Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
    Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
    Darnell G; Richardson DR
    Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy.
    Sandoval-Acuña C; Torrealba N; Tomkova V; Jadhav SB; Blazkova K; Merta L; Lettlova S; Adamcová MK; Rosel D; Brábek J; Neuzil J; Stursa J; Werner L; Truksa J
    Cancer Res; 2021 May; 81(9):2289-2303. PubMed ID: 33685989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
    Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
    J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
    Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
    ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
    Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
    Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelators: correlation between effects on Plasmodium spp. and immune functions.
    Golenser J; Domb A; Mordechai-Daniel T; Leshem B; Luty A; Kremsner P
    J Parasitol; 2006 Feb; 92(1):170-7. PubMed ID: 16629332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of bloodstream forms of Trypanosoma brucei by the iron chelator deferoxamine.
    Breidbach T; Scory S; Krauth-Siegel RL; Steverding D
    Int J Parasitol; 2002 Apr; 32(4):473-9. PubMed ID: 11849643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action of iron (III) chelators as antimalarials: II. Evidence for differential effects on parasite iron-dependent nucleic acid synthesis.
    Lytton SD; Mester B; Libman J; Shanzer A; Cabantchik ZI
    Blood; 1994 Aug; 84(3):910-5. PubMed ID: 8043872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effects of deferoxamine on antibiotic susceptibility in Gram-negative bacteria.
    Erinmez M; Zer Y
    Adv Clin Exp Med; 2024 May; 33(5):491-497. PubMed ID: 37593774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells.
    Glickstein H; Breuer W; Loyevsky M; Konijn AM; Shanzer A; Cabantchik ZI
    Blood; 1996 Jun; 87(11):4871-8. PubMed ID: 8639861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelators as therapeutic agents against Pneumocystis carinii.
    Weinberg GA
    Antimicrob Agents Chemother; 1994 May; 38(5):997-1003. PubMed ID: 8067783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelators in cancer chemotherapy.
    Buss JL; Greene BT; Turner J; Torti FM; Torti SV
    Curr Top Med Chem; 2004; 4(15):1623-35. PubMed ID: 15579100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
    Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triphenylphosphonium-desferrioxamine as a candidate mitochondrial iron chelator.
    Alta RYP; Vitorino HA; Goswami D; Terêsa Machini M; Espósito BP
    Biometals; 2017 Oct; 30(5):709-718. PubMed ID: 28770399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferoxamine inhibits iron-uptake stimulated osteoclast differentiation by suppressing electron transport chain and MAPKs signaling.
    Zhang J; Hu W; Ding C; Yao G; Zhao H; Wu S
    Toxicol Lett; 2019 Oct; 313():50-59. PubMed ID: 31238089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.